Company intelligence / Profile preview

Wave Life Sciences

Singapore City, Singaporewavelifesciences.com ↗

Ownership: Public · WVE
Employees: ~288
Development stage: Phase 2

Overview

Wave Life Sciences has demonstrated positive clinical data across multiple programs. Their WVE-N531 for DMD has shown significant functional benefit and reversal of muscle damage after 48 weeks of dosing. WVE-006 achieved first-ever therapeutic RNA editing in humans in the RestorAATion-2 trial for AATD. The company is advancing WVE-007 for obesity with expected clinical data in the second half of 2025.

Therapeutic areas: CardiovascularMetabolic DisordersEndocrinologyRare DiseasesNeurology
Modalities: RNA editingsplicingRNA interference (RNAi)antisense silencingoligonucleotidesGalNAc-siRNA
Industry: Biotech

Drug pipeline

16 assets

WVE-007

15 more assets in the full pipeline.

Partnerships

GSKTakeda

Financials

Market cap: $635.1M
Total revenue: $42.7M
Enterprise value: $247.6M

Beyond the preview

Go deeper on Wave Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wave Life Sciences.